Skip to main content

Timeline

History of TAK-003 development

Card Image

1987

DEN-2 PDK-53* vaccine developed at Mahidol University, Bangkok, Thailand1

Card Image

2000-2003

Chimeric viruses developed for DENV-1, DENV-3, and DENV-4 on the PDK-53 background2,3

Card Image

September 2016

1st TAK-003 Phase III trial (DEN-301/TIDES)4

Card Image

2019

Primary efficacy endpoint met in TIDES5

Card Image

Today

Ongoing clinical program5

*DEN-2 PDK-53 was initially renamed to DENVax, followed by TDV, and later renamed to TAK-003.1,6-8

NEXT PAGE

Explore the Immune Responses

References

  1. Bhamarapravati N, et al. Bull World Health Organ. 1987;65(2):189–195.
  2. Guirakhoo F, et al. J Virol. 2000;74(12):5477-5485.
  3. Huang CY-H, et al. J Virol. 2003;77(21):11436–11447.
  4. NCT02747927.
  5. Biswal S, et al. N Engl J Med. 2019;381(21):2009-2019.
  6. Osorio JE, et al. Vaccine. 2011;29(42):7251-7260.
  7. Osorio JE, et al. Expert Rev Vaccines. 2016;15(4):497-508.
  8. DeMaso CR, et al. J Infect Dis. 2022;226(11):1959-1963.